Document is current
Any future updates will be listed below
-
Authors
Han, Tianyu
Nebelung, Sven https://orcid.org/0000-0002-5267-9962
Khader, Firas
Wang, Tianci
Müller-Franzes, Gustav https://orcid.org/0000-0002-7413-2570
Kuhl, Christiane
Försch, Sebastian https://orcid.org/0000-0002-4740-6900
Kleesiek, Jens https://orcid.org/0000-0001-8686-0682
Haarburger, Christoph
Bressem, Keno K. https://orcid.org/0000-0001-9249-8624
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
Truhn, Daniel https://orcid.org/0000-0002-9605-0728
- License Information
-
More Information
Article History
Received: 12 May 2024
Accepted: 2 October 2024
First Online: 23 October 2024
Competing interests
: J.N.K. declares consulting services for Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK, and Scailyte, Basel, Switzerland; furthermore J.N.K. holds shares in Kather Consulting, Dresden, Germany; and StratifAI GmbH, Dresden, Germany, and has received honoraria for lectures and advisory board participation by AstraZeneca, Bayer, Eisai, MSD, BMS, Roche, Pfizer and Fresenius. D.T. received honoraria for lectures by Bayer and holds shares in StratifAI GmbH, Germany. The remaining authors declare no competing interests.
